Page 6 - Themis Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Merck is shutting down the programs linked to its two COVID-19 vaccine candidates following early trial data indicating that they failed to generate immune responses comparable to a natural infection or existing vaccines. One of its candidates against COVID-19 was called V590; it built on Merck’s Ebola inoculation platform, while the other one, V591, was based on a measles vaccine used in Europe. Merck, known as MSD outside of the US and Canada, will record a pretax charge in Q4, 2021 as a result of halting the programs related to V591, which it acquired with the...

Share: New York, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cancer Vaccines Global Market Report 2020-30: COVID-19 Growth and Change" - https://www.reportlinker.com/p05995337/?utm_source=GNW 21 billion in 2019 to $4.89 billion in 2020 at a compound annual growth rate (CAGR) of -6.16%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chai...